EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical outcomes, safety, and cost considerations of rhBMP-2 in the surgical management of pyogenic spinal infections: a focused review

Hassan Mahfouz, Hamza Mahfouz, Humaid Al Farii

European Spine Journal · 2025-10 · 34 (10) · 4631-4637

DOI: 10.1007/s00586-025-08993-9 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift European Spine Journal, online erschienen am 12.06.2025. Verfasst von Hassan Mahfouz und 2 weiteren Autor:innen. Beteiligte Einrichtung: King's College London, London, UK. hassan.mahfouz.research@gmail.com. Hauptthemen laut MEDLINE: Bone Morphogenetic Protein 2, Spinal Fusion, Transforming Growth Factor beta, Discitis. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pyogenic spondylodiscitis and vertebral osteomyelitis remain challenging clinical entities, particularly when surgical intervention is required. While recombinant human bone morphogenetic protein-2 (rhBMP-2) is well established in degenerative spinal fusion, its role in the context of active or previously treated spinal infection remains controversial. This focused review evaluates the clinical outcomes, safety profile, and cost considerations of rhBMP-2 in the surgical management of pyogenic spondylodiscitis and vertebral osteomyelitis.

Methods

A focused literature review was conducted to identify studies reporting on the use of rhBMP-2 in patients undergoing spinal fusion for pyogenic spondylodiscitis and vertebral osteomyelitis. Data were extracted on patient demographics, rhBMP-2 dose, fusion rates, complication profiles, infection recurrence, neurological outcomes, and cost-related metrics.

Results

Six retrospective studies encompassing 346 patients treated with rhBMP-2 were included. Fusion rates ranged from 95 to 100%, with a weighted average of 97.84% across reported studies. Infection recurrence was low at 1.54%, and no study attributed reinfection to rhBMP-2 use. The complication rate averaged 18.49%, with only one transient rhBMP-2 related event (radiculitis) reported. Neurological improvement was observed in 68.0% of patients. Cost data, though limited, suggest reduced long-term healthcare utilisation in rhBMP-2 treated patients, potentially offsetting initial implant costs.

Conclusion

Based on currently available retrospective data, rhBMP-2 appears to be a potentially safe adjunct in the surgical management of pyogenic spondylodiscitis and vertebral osteomyelitis. When used selectively, it has been associated with high fusion rates and an acceptable safety profile. These findings support the need for prospective, controlled trials to further define its optimal role, dosing strategies, and cost-effectiveness in the surgical management of pyogenic spondylodiscitis and vertebral osteomyelitis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Bone Morphogenetic Protein 2Spinal FusionTransforming Growth Factor betaDiscitisOsteomyelitisHumansRecombinant ProteinsTreatment Outcome

Stichwörter der Autor:innen

Infection recurrencePyogenic spondylodiscitisRecombinant human bone morphogenetic protein-2 (rhBMP-2)Recombinant human bone morphogenetic protein-2 safetySpinal fusion surgeryVertebral osteomyelitis

Substanzen

Bone Morphogenetic Protein 2Recombinant Proteinsrecombinant human bone morphogenetic protein-2Transforming Growth Factor beta

Autor:innen und Institutionen

  • King's College London, London, UK. hassan.mahfouz.research@gmail.com.
  • Queen Mary University of London, London, UK.
  • Sultan Qaboos University Hospital, Muscat, Oman.

Zitieren

APA

Mahfouz, H., Mahfouz, H., & Al Farii, H. (2025). Clinical outcomes, safety, and cost considerations of rhBMP-2 in the surgical management of pyogenic spinal infections: a focused review. European Spine Journal, 34(10), 4631-4637. https://doi.org/10.1007/s00586-025-08993-9

Vancouver

Mahfouz H, Mahfouz H, Al Farii H. Clinical outcomes, safety, and cost considerations of rhBMP-2 in the surgical management of pyogenic spinal infections: a focused review. European Spine Journal. 2025;34(10):4631-4637. doi:10.1007/s00586-025-08993-9

BibTeX
@article{Mahfouz2025,
  author = {Mahfouz, Hassan and Mahfouz, Hamza and Al Farii, Humaid},
  title = {Clinical outcomes, safety, and cost considerations of rhBMP-2 in the surgical management of pyogenic spinal infections: a focused review},
  journal = {European Spine Journal},
  year = {2025},
  volume = {34},
  number = {10},
  pages = {4631--4637},
  doi = {10.1007/s00586-025-08993-9}
}
Kostenlos starten →